Table 1 Characteristics of enrolled subjects
Variables | COPD (n = 57) | Asthma (n = 89) | P-values |
|---|---|---|---|
Male, n (%) | 43 (75.4) | 43 (48.3) | 0.001 |
Median (IQR) age, years | 73 (66–77) | 59 (51–69) | < 0.0001 |
Median (IQR) BMI, kg/m2 | 27 (24.0–30.8) | 26 (23.0–29.4) | 0.09 |
Median (IQR) pack-year | 38 (23–50) | 0 (0–10) | < 0.0001 |
GOLD stages, % | |||
1 | 33.3 | ||
2 | 56.1 | ||
3 | 10.5 | ||
GOLD categories, % | |||
A | 35.2 | ||
B | 44.4 | ||
C | 9.3 | ||
D | 11.1 | ||
GINA steps, % | |||
1 | 3.8 | ||
2 | 11.4 | ||
3 | 32.9 | ||
4 | 40.5 | ||
5 | 11.4 | ||
Median (IQR) FEV1, L | 1.7 (1.3–2.2) | 2.1 (1.8–3.1) | 0.0001 |
Mean (SD) FEV1, % | 71.7 (19.1) | 88.6 (23.5) | < 0.0001 |
Median (IQR) FVC, L | 3.3 (2.6–3.8) | 3.3 (2.6–4.1) | 0.82 |
Mean (SD) FVC, % | 98.0 (17.2) | 100.8 (20.7) | 0.39 |
Mean (SD) FEV1/FVC | 55.9 (10.1) | 69.6 (10.4) | < 0.0001 |
Median (IQR) blood leucocytes, mmc | 6.7 (5.9–8.1) | 6.9 (5.7–8.0) | 0.96 |
Mean (SD) blood neutrophils, % | 57.5 (9.2) | 53.6 (9.1) | 0.01 |
Mean (SD) blood lymphocytes, % | 28.5 (8.9) | 32.5 (8.1) | 0.006 |
Median (IQR) blood eosinophils, % | 2.9 (1.8–3.9) | 3.6 (2.0–6.0) | 0.047 |
Median (IQR) blood eosinophils, | 210.6 (117.8–307.8) | 238.5 (135.7–427.0) | 0.12 |
Median (IQR) PCR (n = 28 VS. 21) | 0.3 (0.1–0.7) | 0.3 (0.1–0.6) | 0.93 |
Median (IQR) sputum cells, × 104/ml | 204.5 (81.2–330.0) | 125.5 (61–320) | 0.23 |
Median (IQR) sputum macrophages, % | 16.1 (9.7–27.0) | 18.9 (8.8–31.1) | 0.35 |
Median (IQR) sputum neutrophils, % | 74.8 (60.4–82.2) | 58.4 (25.1–74.4) | < 0.0001 |
Median (IQR) sputum eosinophils, % | 1.7 (0.8–3.2) | 4.3 (1.0–24.3) | 0.002 |
Median (IQR) sputum lymphocytes % | 0.8 (0.6–1.7) | 1.4 (0.7–2.0) | 0.12 |
Median (IQR) sputum epithelial cells % | 3.3 (1.4–6.4) | 4.0 (1.7–8.2) | 0.34 |
Inhaled corticosteroids (ICS), % | 10.7 | 85.9 | < 0.0001 |
Exacerbations previous year, yes/no n (%) | 23 (40.4) | 34 (38.2) | 0.88 |
Median (IQR) number of exacerbations during the previous year | 0 (0–1) | 0 (0–1) | 0.86 |